首页 > 用药指导 > 文章详情

Baricitinib(艾乐明)巴瑞替尼是治疗什么病的药

发布时间:2025-04-27 11:49:03 阅读:1306 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

巴瑞替尼片

巴瑞替尼片 生产厂家:孟加拉伊思达(Incepta)制药有限公司 功能主治:JAK1/2抑制剂,用于多种炎症性疾病和自身免疫性疾病 用法用量:用法用量  1、类风湿性关节炎  OLUMIANT的推荐剂量为每日1次口服2mg,餐前餐后都可。  OLUMIANT可以单独使用,也可以与甲氨蝶呤或其他非生物dmard联合使用。  2、COVID-19(新冠病毒)  成人OLUMIANT的推荐剂量为每日一次口服4mg,餐前餐后都可,持续14天或直到出院,以先发生者为准。  3、斑秃  OLUMIANT的推荐剂量是2mg,每天一次口服,餐前餐后都可。  如果对治疗的反应不充分,增加到每天一次4mg。  对于几乎完全或完全的头皮脱发,睫毛或眉毛有或没有大量脱发的患者,考虑每天一次4mg治疗,伴餐前餐后都可。  一旦患者对4mg的治疗产生了充分的反应,将剂量减少到2mg,每天一次。  对于无法吞下整片药片的患者,可以考虑另一种给药方式:  1、口服分散  2、胃造口管(G管)  3、鼻胃管(NG管)或口胃管(OG管)
查看详情

Baricitinib(艾乐明)巴瑞替尼是治疗什么病的药,Baricitinib(Baricitinib)适用于:1、对一种或多种TNF受体阻滞剂反应不足的中度至重度活动性类风湿性关节炎成人患者的治疗;2、需要补充氧气、无创或有创机械通气(ECMO)的住院成人的COVID-19(新冠病毒)治疗;3、成人重度斑秃患者的治疗。

Baricitinib (brand name Olumiant) is a medication used to treat various conditions, including rheumatoid arthritis, COVID-19, and alopecia areata. This article will explore the uses of Baricitinib and its effectiveness in treating these diseases.

1. Introduction

Baricitinib (Olumiant) is a medication that has shown promise in the treatment of several diseases.

This article will discuss the different conditions for which Baricitinib is prescribed and its potential benefits.

2. Baricitinib for Rheumatoid Arthritis

Rheumatoid arthritis is a chronic autoimmune disease that causes joint inflammation and pain.

Baricitinib is an FDA-approved medication for the treatment of moderate to severe rheumatoid arthritis in adults.

It works by inhibiting Janus kinase (JAK) enzymes, which are involved in the immune response.

Baricitinib helps reduce inflammation and relieve symptoms, such as joint swelling, pain, and stiffness.

Clinical trials have shown that Baricitinib can improve physical function and slow the progression of joint damage in patients with rheumatoid arthritis.

3. Baricitinib for COVID-19

During the COVID-19 pandemic, researchers investigated the potential of repurposing existing drugs to treat the virus.

Baricitinib showed promise in reducing inflammation and the hyperactive immune response seen in severe COVID-19 cases.

In November 2020, the FDA issued an emergency use authorization for Baricitinib in combination with remdesivir for hospitalized COVID-19 patients requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Combination therapy with Baricitinib and remdesivir has demonstrated a reduced recovery time in hospitalized COVID-19 patients compared to remdesivir alone.

4. Baricitinib for Alopecia Areata

Alopecia areata is an autoimmune condition that leads to sudden hair loss, often in patches on the scalp.

Baricitinib has shown potential as a treatment for alopecia areata by modulating the immune system's response and minimizing inflammation.

Several case studies and small clinical trials have reported positive outcomes, with hair regrowth observed in patients after using Baricitinib.

However, further research is needed to determine the optimal dosage, long-term safety, and effectiveness of Baricitinib for treating alopecia areata.

In conclusion, Baricitinib (Olumiant) is a versatile medication used for the treatment of rheumatoid arthritis, COVID-19, and alopecia areata. It has demonstrated efficacy in reducing inflammation, alleviating symptoms, and improving clinical outcomes in patients with these conditions. However, it is important to consult with a healthcare professional to determine the appropriate use and dosage of Baricitinib, considering individual patient factors and potential side effects.